PubRank

Martin Tolstrup

Author PubWeight™ 21.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 2013 1.53
2 Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis 2010 1.52
3 Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient. Clin Infect Dis 2008 1.16
4 Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother 2013 1.12
5 Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One 2012 1.12
6 Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune Defic Syndr 2011 0.96
7 Endotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals. PLoS One 2011 0.93
8 Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis 2011 0.88
9 Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS One 2013 0.88
10 Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis 2013 0.85
11 The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adults. PLoS One 2012 0.83
12 HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. AIDS 2016 0.81
13 Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection. AIDS Res Hum Retroviruses 2012 0.80
14 ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions. J Clin Invest 2016 0.80
15 Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles. Virol J 2011 0.79
16 Timing of Toll-like receptor 9 agonist administration in pneumococcal vaccination impacts both humoral and cellular immune responses as well as nasopharyngeal colonization in mice. Infect Immun 2012 0.78
17 TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults. Hum Vaccin Immunother 2012 0.78
18 Population-based study of diagnostic assays for Borrelia infection: comparison of purified flagella antigen assay (Ideia, Dako Cytomation) and recombinant antigen assay (Liaison, DiaSorin). BMC Clin Pathol 2008 0.78
19 The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients. AIDS 2015 0.78
20 Polymers fight HIV: potent (pro)drugs identified through parallel automated synthesis. Adv Healthc Mater 2014 0.77
21 Construction of a gammaretrovirus with a novel tropism and wild-type replication kinetics capable of using human APJ as entry receptor. J Virol 2012 0.77
22 Disulfide reshuffling triggers the release of a thiol-free anti-HIV agent to make up fast-acting, potent macromolecular prodrugs. Chem Commun (Camb) 2014 0.76
23 Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations. AIDS 2017 0.75
24 Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission. PLoS Pathog 2016 0.75
25 HIV-1 reverse transcriptase gene 103K/N and 184M/V combinations in tandem: detection and quantification of HIV-1 populations in the CD45RO+ T-cell compartment by a double-ARMS real-time PCR assay. J Acquir Immune Defic Syndr 2006 0.75
26 Beyond antiretroviral therapy: Early interventions to control HIV-1 infection. AIDS 2017 0.75
27 Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells. Adv Healthc Mater 2014 0.75
28 New insights on the phenotype of HIV reservoirs. AIDS 2016 0.75
29 Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations. AIDS 2017 0.75